This excerpt taken from the ABII 10-K filed Mar 12, 2010.
Specialised Therapeutics of Australia, Pty Ltd.
In February 2008, we entered into an exclusive license agreement with Specialised Therapeutics of Australia, Pty Ltd. under which we granted Specialised Therapeutics the right to market and sell Abraxane® in Australia and New Zealand. In October 2008, the Therapeutic Goods Administration (TGA) in Australia approved Abraxane® for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. In February 2009, we launched Abraxane® in Australia through Specialised Therapeutics.